We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Quark Biotech (creating treatments for fibrotic and ischemic conditions in the eyes, kidney, and lungs) has received rights to use Alnylam Pharmaceuticals's (developing RNAi drug candidates for respiratory, neurological, cardiovascular, and musculoskeletal conditions and infectious diseases) RNAi patents--through the InterfeRx licensing program--to discover, develop, and market RNAi therapeutics that target p53 and RTP801 genes.
Deal Industry
Pharmaceuticals
Biotechnology
Antisense, Oligonucleotides
Large Molecule
Deal Status
Final
Deal Type
Alliance
Includes Contract
Intra-Biotech Deal
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?